Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report

Cancer Chemother Pharmacol. 2003 Jun;51(6):525-9. doi: 10.1007/s00280-003-0578-z. Epub 2003 May 15.


Purpose: BNP7787 (2',2'-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin.

Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode.

Results: After the i.v. administration of 41 g/m(2) BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The AUC( infinity ) of mesna was approximately 8% of the AUC( infinity ) of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration.

Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmacokinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antineoplastic Agents / pharmacology
  • Area Under Curve
  • Ascites / metabolism*
  • Chromatography, High Pressure Liquid
  • Cisplatin / pharmacology
  • Electrochemistry
  • Half-Life
  • Humans
  • Male
  • Mesna / analogs & derivatives*
  • Mesna / blood
  • Mesna / pharmacokinetics*


  • Antineoplastic Agents
  • 2,2'-dithiodiethanesulfonic acid
  • Mesna
  • Cisplatin